EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation

Kristen Thane iD, Rebecca Voth, Rebecca Klee iD, Tobias Warnken iD, Victor Chukwu, Nicholas Frank iD

Journal of Veterinary Internal Medicine · 2025-11-01 · 39 (6)

DOI: 10.1111/jvim.70256 ↗

At a glance

Journal article in Journal of Veterinary Internal Medicine, published online on 2025-11-01. Written by Kristen Thane and 5 co-authors. Institution: Cummings School of Veterinary Medicine, Tufts University, Grafton, Massachusetts, USA. Major MEDLINE topics: Bridged Bicyclo Compounds, Heterocyclic, Horse Diseases, Hyperinsulinism, Insulin. Cited 12 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Boehringer Ingelheim Animal Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are promising treatments to manage hyperinsulinemia in horses with insulin dysregulation (ID). Hypothesis The SGLT2i velagliflozin decreases insulin concentration in horses with ID. Animals Privately-owned adult horses (n = 37) with laboratory-confirmed ID (low-dose oral sugar test insulin concentration > 75 μIU/mL).

Methods

Double-blind randomized placebo-controlled trial. Horses received placebo (n = 19) or velagliflozin 0.3 mg/kg PO q24h (n = 18) for 20 weeks (Study Period 1, SP1) immediately followed by a 20-week open-label trial where all animals received velagliflozin (SP2). Analysis of resting insulin, glucose, and triglyceride concentrations and body condition score (BCS) was performed between treatment groups and study periods using a Mann–Whitney U test. For SP1, analysis of changes in biochemical analytes over time was performed using generalized linear mixed effects models (GLMM). Data are reported as median (interquartile range).

Results

In SP1, GLMM indicated a significant effect of treatment on insulin concentration (71 [33–131] μIU/mL in horses receiving velagliflozin and 157 [82–298] μIU/mL in horses receiving placebo; p < 0.0001). The average (95% confidence interval [CI]) effect of velagliflozin treatment on insulin concentration was 155 (90–219) μIU/mL. Horses receiving placebo in SP1 had lower insulin (50 [26–99] μIU/mL) during SP2 (p < 0.0001). All horses experienced a transient increase in serum triglyceride concentration during velagliflozin treatment with no clinical abnormalities reported. In SP1, larger decreases in BCS occurred in horses receiving velagliflozin (median BCS 1 point lower than baseline; p = 0.02) than those receiving placebo.

Conclusions

Velagliflozin significantly decreased resting insulin concentrations in horses with ID.

Subjects

MeSH terms (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicHorse DiseasesHyperinsulinismInsulinSodium-Glucose Transporter 2 InhibitorsAnimalsFemaleMaleBlood GlucoseDouble-Blind MethodHorses

Author keywords

endocrinologyequine metabolic syndromeinsulin dysregulationlaminitisoral sugar test

Substances

Blood GlucoseBridged Bicyclo Compounds, HeterocyclicInsulinSodium-Glucose Transporter 2 Inhibitors

Authors and institutions

  • Cummings School of Veterinary Medicine, Tufts University, Grafton, Massachusetts, USA.
  • Boehringer Ingelheim Animal Health USA, Duluth, Georgia, USA.
  • Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.
  • College of Veterinary Medicine, Mississippi State University, Starkville, Mississippi, USA.

ORCID profiles: Kristen Thane, Rebecca Klee, Tobias Warnken, Nicholas Frank

Funding

  • Boehringer Ingelheim Animal Health

Cite

APA

Thane, K., Voth, R., Klee, R., Warnken, T., Chukwu, V., & Frank, N. (2025). Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation. Journal of Veterinary Internal Medicine, 39(6). https://doi.org/10.1111/jvim.70256

Vancouver

Thane K, Voth R, Klee R, Warnken T, Chukwu V, Frank N. Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation. Journal of Veterinary Internal Medicine. 2025;39(6). doi:10.1111/jvim.70256

BibTeX
@article{Thane2025,
  author = {Thane, Kristen and Voth, Rebecca and Klee, Rebecca and Warnken, Tobias and Chukwu, Victor and Frank, Nicholas},
  title = {Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2025},
  volume = {39},
  number = {6},
  doi = {10.1111/jvim.70256}
}
Start for free →